Quintrio
Home

SERVICES-BUSINESS SERVICES, NEC

OptimizeRx Corporation Common Stock

OPRX

OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.

Last trade $6.85
Day change +$0.205 (+3.09%)
Day range $6.52 – $7.00
Volume 108,309
Market cap $126M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$125.54M
Price / earnings
25.02×
Price / book
0.94×
Price / sales
1.33×
EV / sales
1.23×
EV / EBITDA
7.16×

Profitability

Earnings per share
$0.27
Return on assets
3.1%
Return on equity
3.75%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.1×
Current ratio
5.06×
Quick ratio
5.06×
Cash ratio
2.13×

Cash flow

Price / cash flow
6.29×
Price / free cash flow
6.31×
Free cash flow
$19.89M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for OPRX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$21.62M$20.5M$19.84M$32.24M$26.07M$29.2M$21.93M$32.32M
Cost of revenue$5.37M$4.82M$4.91M$8.14M$8.55M$10.56M$8.58M$10.29M
Gross profit$16.25M$15.69M$14.93M$24.1M$17.52M$18.64M$13.34M$22.02M
Selling, general and administrative$7.8M$11.44M$10.07M$14.09M$9.69M$11.26M$11.1M$17.3M
Research and development$2.93M$3.27M$3.4M$0$2.72M$3.09M$3.25M$0
Total operating expenses$13.58M$15.78M$14.54M$15.53M$15.45M$15.43M$15.45M$18.39M
Operating income$2.67M-$88K$396K$8.57M$2.07M$3.21M-$2.1M$3.63M
Interest expense-$177K-$1.13M-$1.16M-$1.24M-$1.15M-$1.6M-$1.3M-$1.56M
Income before taxes$2.57M-$1.1M-$644K$7.47M$1.07M$1.73M-$3.27M$2.21M
Income taxes$1.37M-$393K-$149K$2.45M$291K$199K-$1.07M$2.29M
Net income$1.2M-$703K-$495K$5.02M$779K$1.53M-$2.2M-$78K
Net income attributable to common shareholders$1.2M-$703K-$495K$5.02M$779K$1.53M-$2.2M-$78K
EBITDA$3.73M$976K$1.46M$10.02M$3.15M$4.28M-$1.01M$4.73M
Basic earnings per share$0.06-$0.04-$0.03$0.27$0.04$0.08-$0.12$0.00
Diluted earnings per share$0.06-$0.04-$0.03$0.26$0.04$0.08-$0.12$0.00

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

OptimizeRx Corp. (OPRX) Q3 Earnings and Revenues Beat Estimates

OptimizeRx (OPRX) beat Q3 2026 earnings expectations with $0.2 EPS versus consensus of $0.18, though revenues declined year-over-year to $21.62M from $26.07M. Despite beating estimates, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The stock has underperformed the S&P 500 by 33.6% year-to-date. Smith Micro Software (SMSI) is expected to report a quarterly loss of $0.11 per share.

Zacks Investment Research

Satellogic Inc. (SATL) Reports Q3 Loss, Beats Revenue Estimates

Satellogic Inc. (SATL) reported a quarterly loss of $0.03 per share, missing consensus estimates by 200%, though revenues of $16.04 million exceeded expectations by 14.46%. The stock has gained 112% year-to-date, significantly outperforming the S&P 500's 10.3% gain. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market. The Satellite and Communication industry ranks in the top 22% of Zacks industries.

Zacks Investment Research

Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?

The Trade Desk (TTD) is strengthening its healthcare advertising position through a new integration with OptimizeRx (OPRX), giving advertisers access to authenticated healthcare professional inventory across 400+ EHR systems reaching ~800,000 verified HCPs. The inventory will be available via TTD's OpenPath platform in Q4 2026. This partnership complements TTD's recent expansions with Veeva Crossix and IQVIA Digital, potentially attracting more pharma and life sciences advertisers. However, TTD shares have declined 71.9% over the past year and carry a Zacks Rank #4 (Sell) rating.

GlobeNewswire Inc.

OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET

OptimizeRx Corp. (Nasdaq: OPRX) announced it will hold a conference call on August 12, 2026, at 4:30 p.m. ET to discuss its second quarter 2026 financial results ended June 30, 2026. The call will include management remarks followed by a Q&A session, with details and webcast access provided for investors.

GlobeNewswire Inc.

OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer

OptimizeRx Corp. announced the appointment of Sarah Bast as Chief Marketing Officer. Bast brings over 20 years of pharmaceutical marketing experience from roles at Publicis Health Media and major life sciences companies including Lilly, Bayer, Johnson & Johnson, and AstraZeneca. She will lead OptimizeRx's marketing strategy and go-to-market initiatives as the company expands its point-of-care technology solutions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
May 14, 20181-for-3reverse split